dasiglucagon

01/01/2023 - "Dasiglucagon offers safe and effective treatment for severe hypoglycemia in patients aged 6 years and older. "
01/01/2023 - "We searched PubMed, Cochrane Library, Embase, and ClinicalTrials.gov for randomized controlled trials (RCTs) investigating the safety and efficacy of dasiglucagon in the treatment of hypoglycemia in patients with T1DM. "
01/01/2022 - "Methods: In an open label, randomized, crossover, comparative device handling study, trained caregivers and untrained bystanders administered the dasiglucagon autoinjector or Eli Lilly GEK to manikins in a simulated emergency hypoglycemia situation. "
01/01/2022 - "Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial."
08/01/2020 - "This review summarizes the reported studies associated with the pharmacokinetics, pharmacodynamics, safety, and tolerability characteristics, as well as clinical application of dasiglucagon for managing diabetic hypoglycemia. "

01/01/2023 - "The objective of this trial was to evaluate the efficacy, safety and feasibility of pen-administered low-dose dasiglucagon for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions. "
01/01/2023 - "Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial."
10/01/2021 - "In this double-blind trial, 45 participants with type 1 diabetes were randomized 3:1 to receive a single subcutaneous dose of dasiglucagon 0.6 mg or placebo following controlled induction of hypoglycaemia. "
01/01/2023 - "Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes."
10/01/2021 - "Dasiglucagon provided rapid reversal of hypoglycaemia in adults with type 1 diabetes. "

11/01/2023 - "Dasiglucagon for the treatment of congenital hyperinsulinism: a randomised phase 3 trial in infants and children."
06/01/2021 - "Dasiglucagon (Zegalogue®) is an antihypoglycaemic agent being developed by Zealand Pharma for the treatment of hypoglycaemia, type 1 diabetes mellitus (T1DM) management and congenital hyperinsulinism. "

12/01/2023 - "Dasiglucagon was generally well tolerated, with mostly mild to moderate adverse events of nausea. "
01/01/2023 - "Dasiglucagon use was safe and well tolerated with mild nausea being the most frequent adverse effect. "
01/01/2022 - "Episodes of nausea were numerically, but not significantly, higher after dasiglucagon administration. "
07/01/2022 - "Dasiglucagon was well tolerated and the common adverse events included nausea and vomiting."
08/01/2020 - "Dasiglucagon is safe and well tolerated with the main adverse effects being nausea and vomiting. "

07/01/2022 - "Dasiglucagon was well tolerated and the common adverse events included nausea and vomiting."
08/01/2020 - "Dasiglucagon is safe and well tolerated with the main adverse effects being nausea and vomiting. "
01/01/2023 - "The most common adverse events with dasiglucagon were nausea, vomiting, and headache; no serious safety events were observed. "
10/01/2021 - "As expected for glucagon treatment, nausea and vomiting were common adverse events in dasiglucagon-treated participants. "
01/01/2019 - "Nausea and vomiting occurred more frequently with dasiglucagon than with commercial glucagon at identical doses which might be attributable to dasiglucagon's higher potency. "